{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:46:58Z","timestamp":1782776818345,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejogrb.2026.115045","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:02:50Z","timestamp":1772294570000},"page":"115045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival trends among patients with newly diagnosed stage IVB cervical cancer before and after the approval of bevacizumab and immunotherapy"],"prefix":"10.1016","volume":"321","author":[{"given":"San-Gang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0751-1033","authenticated-orcid":false,"given":"Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejogrb.2026.115045_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102751","article-title":"Global, regional, and national burden of cervical cancer in 2022 and projections to 2050: a population-based analysis of GLOBOCAN","volume":"36","author":"Son","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115045_b0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2019.08.022","article-title":"Primary treatment patterns and survival of cervical cancer in Sweden: a population-based Swedish Gynecologic Cancer Group Study","volume":"155","author":"Bjurberg","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2026.115045_b0015","article-title":"Rethinking treatment approaches for FIGO stage IVB cervical cancer: personalized strategies and emerging therapies","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115045_b0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/ijgo.70077","article-title":"The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer","volume":"170","author":"Miyoshi","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2026.115045_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2025.05.007","article-title":"Redefining stage IVB cervical cancer: the unique prognosis of distant lymph node metastasis which is comparable to stage IIIC","volume":"198","author":"Gu","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115045_b0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s11864-025-01325-5","article-title":"Management of Stage IVB Cervical Cancer Including the Role of Radiotherapy","volume":"26","author":"Gardner","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejogrb.2026.115045_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygyno.2024.10.023","article-title":"Standard of care treatment for stage IVB cervical cancer: a systematic review and meta-analysis","volume":"191","author":"Hunsberger","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ejogrb.2026.115045_b0040","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115045_b0045","first-page":"185","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 Randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"J Am Med AssocOncol"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115045_b0050","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"9376","key":"10.1016\/j.ejogrb.2026.115045_b0055","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(03)13778-6","article-title":"Cervical cancer","volume":"361","author":"Waggoner","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2026.115045_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.ejogrb.2026.115045_b0065","first-page":"77","article-title":"Advances in cervical cancer: current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"CancerCommun (Lond)"},{"key":"10.1016\/j.ejogrb.2026.115045_b0070","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Registries, Nov 2024 Sub (2000-2022), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2025, based on the November 2024 submission."},{"key":"10.1016\/j.ejogrb.2026.115045_b0075","unstructured":"FDA News Release. FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer. US Food and Drug Administration.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm410121.htm [access date, 13 Sep 2025]."},{"issue":"17","key":"10.1016\/j.ejogrb.2026.115045_b0080","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejogrb.2026.115045_b0085","unstructured":"FDA News Release. FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy.https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm610572.htm [access date, 13 Sep 2025]."},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115045_b0090","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2022.04.013","article-title":"Local treatment improves survival in patients with stage IVB cervical cancer","volume":"165","author":"Xu","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115045_b0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ijgo.15121","article-title":"Local treatment strategies in Stage IVB cervical squamous cell carcinoma and adenocarcinoma","volume":"164","author":"Xu","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2026.115045_b0100","article-title":"Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO, 2018): a two-center retrospective study","volume":"2025","author":"Nakashima","year":"2018","journal-title":"Jpn J Radiol"},{"issue":"3","key":"10.1016\/j.ejogrb.2026.115045_b0105","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.3802\/jgo.2025.36.e42","article-title":"Different surgical methods for FIGO stage IVB cervical cancer patients receiving chemotherapy: a population-based study","volume":"36","author":"Li","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"10103","key":"10.1016\/j.ejogrb.2026.115045_b0110","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"10421","key":"10.1016\/j.ejogrb.2026.115045_b0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ejogrb.2026.115045_b0120","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2026.115045_b0125","article-title":"Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors","volume":"92","author":"Adhikari","year":"2024","journal-title":"CancerEpidemiol"},{"key":"10.1016\/j.ejogrb.2026.115045_b0130","doi-asserted-by":"crossref","unstructured":"Kalantri S, Pachika P, Jones T, et al. Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era: Persistent Racial and Socioeconomic Disparities. JCO Oncol Pract. 2025:OP2500433. doi: 10.1200\/OP-25-00433.","DOI":"10.1200\/OP-25-00433"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115045_b0135","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35476","article-title":"Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and end results database-based study","volume":"131","author":"Wang","year":"2025","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.ejogrb.2026.115045_b0140","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: final overall Survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115045_b0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/JS9.0000000000000774","article-title":"Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study","volume":"110","author":"Deng","year":"2024","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.ejogrb.2026.115045_b0150","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejogrb.2026.115045_b0155","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8+Tcell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211526001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:09:44Z","timestamp":1782774584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211526001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0301211526001119"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115045","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival trends among patients with newly diagnosed stage IVB cervical cancer before and after the approval of bevacizumab and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2026.115045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115045"}}